Endoscopic vs Surgical Treatment for Low-Grade Bladder Cancer

By Guy Verhovsky, MD - Last Updated: April 11, 2024

Michael Grasso, MD, and Guy Verhovsky, MD, discuss their recent research, presented at the European Association of Urology (EAU) Congress 2024, on the potential of endoscopic treatment with surveillance for patients with urothelial carcinoma (UC).

They also explain what treatment options current EAU and National Comprehensive Cancer Network guidelines recommend for those with high-risk UC.

BRAVO Study: Blue Light Cystoscopy Reduces Recurrence in Patients With NMIBC

Emily MenendezUrothelial Carcinoma Diagnostics | March 20, 2025

Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.

Bladder-Sparing Innovations in MIBC: Dr. Elizabeth Plimack on the RETAIN Approach and Its Future

Elizabeth Plimack, MD, MS, FASCOMuscle Invasive Urothelial Carcinoma | March 17, 2025

Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.

Pioneering Advances in Bladder Cancer: New Drug Classes, Biomarkers, and Treatment Models

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel elaborates on what excites them most about the future of UC research, highlighting promising advancements.

Utility of ctDNA, Overcoming Barriers to Multidisciplinary Care in Community, Academic Settings

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 21, 2025

The panel considers the evolving role of ctDNA in guiding adjuvant therapy decisions, highlighting IMvigor011 and MODERN.

Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions

Petros Grivas, MD, PhDAdvanced Urothelial Carcinoma | March 13, 2025

The panel shares the NIAGARA findings and results from RETAIN-2 on dose-dense MVAC for bladder preservation.

Endoscopic vs Surgical Treatment for Low-Grade Bladder Cancer

Related Posts